Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Vikas-Gupta"

13 News Found

Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’
News | March 13, 2025

Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’

Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure


IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr
News | February 14, 2025

IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr

Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24


Alkem launches Kojiglo serum to manage facial hyperpigmentation
News | February 05, 2025

Alkem launches Kojiglo serum to manage facial hyperpigmentation

This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology


IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr
News | November 16, 2024

IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr

Total Income in Q2 FY25 stood at Rs. 532.18 crore


Alkem signs license agreement with Takeda to commercialise Vonoprazan in India
News | September 04, 2024

Alkem signs license agreement with Takeda to commercialise Vonoprazan in India

Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)


IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
News | August 10, 2024

IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr

The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24


IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
News | February 07, 2024

IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24

The company recently received CEP certificate approval for Losartan Potassium by EDQM


IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
News | November 15, 2023

IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr

EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ


IOL Chemicals and Pharmaceuticals posts Q1 FY24 consolidated PAT at Rs. 45.86 Cr
News | August 10, 2023

IOL Chemicals and Pharmaceuticals posts Q1 FY24 consolidated PAT at Rs. 45.86 Cr

IOL Chemicals and Pharmaceuticals has reported total income of Rs. 570.24 crores during the period ended June 30, 2023


CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
News | July 05, 2023

CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals

The 'A+' rating reflects IOL's robust business model, diversified product portfolio